Key takeaways
- Lecanemab (Leqembi) and donanemab (Kisunla) are approved only for MCI or mild dementia due to Alzheimer's disease, with amyloid confirmed by testing.
- They can modestly slow decline; they do not stop or reverse the disease. Experts still debate how meaningful the benefit is.
- Brain swelling or small bleeds (ARIA) are the main risk, so regular MRI monitoring is required.
- Since July 2026, lecanemab can be started as an under-the-skin injection that can be given at home.
For decades, Alzheimer's medicines could only ease symptoms for a while. The anti-amyloid antibodies are different: they target amyloid, one of the proteins that builds up in the brain in Alzheimer's disease. That is real scientific progress. It also comes with real trade-offs, and families deserve a clear picture of both.
What these medicines are
Lecanemab (brand name Leqembi) and donanemab (brand name Kisunla) are lab-made antibodies that help the immune system clear amyloid plaques from the brain. They are approved by the FDA for people with mild cognitive impairment or mild dementia due to Alzheimer's disease — the early stages studied in the clinical trials[1][2]. They are not approved for people without symptoms, and they have not been shown to help people at later stages.
How they are given
- Donanemab is given as an intravenous (IV) infusion every four weeks[1]. In July 2025 the FDA approved a label update with a more gradual starting dose schedule designed to lower the risk of brain swelling[3]. Expert recommendations say doctors may consider stopping treatment once a PET scan shows amyloid has been cleared, which often happens within 12 to 18 months[4].
- Lecanemab began as an IV infusion every two weeks. In August 2025 an under-the-skin (subcutaneous) autoinjector called Leqembi Iqlik was approved for maintenance doses. On July 13, 2026, the FDA also approved it as a starting dose. People can now begin with weekly injections that can be given at home, with a health care provider guiding at least the first two doses, or with IV infusions every two weeks[2].
How much do they help?
In the large trials that led to approval, both medicines slowed decline on measures of memory, thinking and daily function over about 18 months, compared with placebo. They did not stop the disease or restore lost abilities[4][5].
Experts disagree about how much that slowing means in daily life. In April 2026, a Cochrane systematic review that pooled 17 studies of this whole class of drugs concluded that the effect on thinking and dementia severity at 18 months was "trivial" and the effect on daily function "small at best", and that the drugs increase brain swelling and microbleeds[6]. Other leading experts and Alzheimer's organizations have strongly disputed that conclusion. They point out that the review combined older antibodies that failed with the newer ones that succeeded. Regulators in the US and elsewhere have judged the benefit of lecanemab and donanemab to be modest but meaningful for carefully selected patients[7].
These medicines can buy time. They do not turn back the clock. Whether that time is worth the effort and the risk is a personal decision, and it deserves an unhurried conversation.
The main risk: ARIA
Both drugs carry a boxed warning — the FDA's strongest — for amyloid-related imaging abnormalities (ARIA)[1]. ARIA means temporary swelling in areas of the brain (ARIA-E) or small spots of bleeding (ARIA-H). Most ARIA causes no symptoms and is found on scheduled MRI scans. Some people get headaches, confusion, dizziness, vision changes or nausea. Rarely, ARIA causes seizures or serious, even life-threatening, bleeding or swelling.
- Genetics matter. People with two copies of the APOE ε4 gene have a higher risk of ARIA, so the FDA recommends APOE testing before starting treatment[1].
- Blood thinners matter. Expert appropriate-use recommendations advise against starting these drugs in people who take anticoagulant blood thinners, because of the risk of bleeding in the brain[5].
- MRI monitoring is required. Patients need a recent brain MRI before starting and repeat MRIs on a set schedule during the first months of treatment[4][5].
Who may be a candidate
The appropriate-use recommendations written by independent experts describe careful selection[4][5]. In general, a candidate:
- has MCI or mild dementia, with a diagnosis of Alzheimer's disease made by a clinician experienced in memory disorders;
- has amyloid confirmed by an amyloid PET scan or a spinal-fluid test;
- has a brain MRI without findings that raise the bleeding risk too far, such as more than four microbleeds;
- has a care partner and can attend infusions or injections, MRIs and follow-up visits;
- understands the potential benefits and risks and chooses treatment through shared decision-making.
The FDA also encourages patients and clinicians to take part in ALZ-NET, a registry that tracks how people do on these treatments in everyday practice[2].
Questions to bring to your appointment
- Is my diagnosis confirmed with an amyloid test, and what stage am I at?
- What is my APOE status, and how does it change my risk?
- Which of my current medicines could interact, especially blood thinners?
- How often will I need MRIs, infusions or injections, and where?
- What will it cost with my insurance, including scans and visits?
- What would we watch for to decide whether to continue or stop?
Choosing not to start an anti-amyloid medicine is also a reasonable, informed choice. Good care for memory loss continues either way.
When to see a doctor
Talk with a memory specialist if you have MCI or mild dementia and want to know whether these medicines could fit you. If you are receiving one and develop a new headache, confusion, vision changes, dizziness, nausea or a seizure, contact your care team right away or call 911 for severe symptoms.
Sources
- U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer's disease (Kisunla, donanemab-azbt). July 2, 2024. View source (opens in a new tab)
- Alzheimer's Association. Alzheimer's Association welcomes FDA approval of Leqembi subcutaneous starter dose. July 13, 2026. View source (opens in a new tab)
- NeurologyLive. FDA approves updated label for donanemab with modified titration to lower ARIA-E risk. July 2025. View source (opens in a new tab)
- Rabinovici GD, Selkoe DJ, Schindler SE, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;12(5):100150. View source (opens in a new tab)
- Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. View source (opens in a new tab)
- Nonino F, Minozzi S, Sambati L, et al. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2026;(4):CD016297. View source (opens in a new tab)
- The Pharmaceutical Journal. Amyloid-targeting Alzheimer's drugs 'probably' not effective, review finds (with expert responses). April 16, 2026. View source (opens in a new tab)
General education for adults and families, not personal medical advice. Opinions are Dr. Aggarwal's own and not those of Rush University Medical Center. In an emergency, call 911.